Warning

1. Assess risk associated with source non-human primate

Below is the source risk for any macaque from a research or zoo setting. If patient is coming from Charles River laboratory, this information will be on the Non-Human Primate (NHP) Incident Report.

Note: If you are viewing this table on a tablet or mobile phone, turn it to landscape to view the table better.

 

Any Macaque in research or zoo setting

Previous herpes B virus serology result

Negative

at final 3 month test

Thought negative

Previously neg, but not had final 3 month test

Not tested

From a herpes B negative colony (Mauritian/ Gibraltarian)

Not known

Non-Mauritian/ Gibraltarian and no test results available

Species of NHP

Mauritian/ Gibraltarian macaque – NO contact with other macaque species
eg Charles River Mauritian macaque

OR contact only with other macaques with completed testing

N/A N/A Negligible risk N/A
Non-Mauritian/ Gibraltarian macaque OR origin unknown – No contact with other macaques since last test OR
Contact only with other macaques that have completed testing
eg Charles River Asian macaque
Negligible risk Possible risk N/A Possible risk

 

If ‘negligible risk’ no further risk assessment is needed.

If ‘possible risk’ proceed to step 2.

 

2. Assess injury risk

(Based on recommendations from Cohen et al):

Skin exposures where skin remains intact do not carry a risk of transmission and no further assessment or follow up is required.

For all other injuries, proceed to the injury risk assessment below

Note: If you are using a mobile phone or tablet you may wish to turn the device to landscape to view the tables on this page better.

 

Source animal
Healthy macaque 0
Macaque that is ill or immunocompromised 1
Macaque that is known to be shedding herpes B virus 1
Macaque that has lesions compatible with herpes B virus disease 1
Test results from vet indicates macaque is infected with herpes B virus 1

Injury
Skin exposure in which skin remains intact Not at risk: leave risk assessment
Mucosal exposure 1
Needlestick involving blood 1
Laceration (with loss of skin integrity) in any location other than head, neck or torso 1
Puncture or laceration occurring after exposure to objects (a) contaminated with body fluid (other than that from a lesion), or (b) potentially infected cell culture 1
Laceration of head, neck or torso 2
Deep puncture bite in any location 2
Needlestick associated with tissue/fluid from nervous system, lesions suspicious for B virus, eyelids or mucosa 2
Puncture or laceration after exposure to objects (a) contaminated either with fluid from monkey oral or genital lesions or with nervous system tissues, or (b) known to contain B virus 2

First aid  
Adequately cleaned 0
Inadequately cleaned 1

 

Suggested actions: 

Total score Risk assessment Recommended actions
2 or more High Commence postexposure prophylaxis: aciclovir 800mg five times daily for 14 days, or valaciclovir 1gram three times daily for 14 days
1 Moderate No prophylaxis, follow up required
0 Low No prophylaxis. Give patient advice. No follow up required.

Treatment of possible cases of Herpes B disease

Any patients presenting with fever, flu-like symptoms, vesicles at site of injury or signs of encephalopathy following an injury with a non-human primate should be immediately discussed with the ID registrar on-call (pager 8161 9am-7pm, ID Consultant on-call via switchboard out with these).

Assess Rabies risk as per PHE rabies post-exposure guidelines

Follow *NHS Lothian antimicrobial guidelines for management of animal bites (For prophylaxis use the recommendations for human bites).

All monkey bites are considered “tetanus prone”. Recommended actions are given in the table below and are based on PHE guidance.

 

Vaccination status Immediate treatment
Those aged 11 years and over, who have received an adequate priming course of tetanus vaccine with the last dose within the last 10 years None required

Received adequate priming course of tetanus vaccine but last dose more than 10 years ago

(Includes UK born after 1961 with history of accepting vaccinations)

Immediate reinforcing dose of vaccine

Not received adequate priming course
of tetanus vaccine

(Includes uncertain immunisation status and/or born before 1961)

Immediate reinforcing dose of vaccine

One dose of human tetanus immunoglobulin in a different site

 

Editorial Information

Last reviewed: 25/06/2024

Next review date: 26/06/2025

Author(s): Dr Katherine Hill, Dr Oliver Koch, Dr Jenny Poller.

Version: 2.0

Reviewer name(s): Dr Oliver Koch.